Sumitomo Mitsui Trust Group Inc. Increases Holdings in Insulet Corporation $PODD

Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Insulet Corporation (NASDAQ:PODD) by 0.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,573 shares of the medical instruments supplier’s stock after acquiring an additional 911 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.23% of Insulet worth $50,449,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PODD. Larson Financial Group LLC boosted its stake in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the 1st quarter worth approximately $26,000. SouthState Corp boosted its stake in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Kozak & Associates Inc. purchased a new stake in Insulet in the 2nd quarter valued at approximately $32,000. Finally, Trust Co. of Toledo NA OH purchased a new stake in Insulet in the 2nd quarter valued at approximately $35,000.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on PODD shares. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Oppenheimer upped their target price on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Canaccord Genuity Group upped their target price on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Rothschild & Co Redburn upped their target price on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Insulet in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $352.11.

Insulet Trading Up 1.5%

PODD stock opened at $325.80 on Tuesday. The company has a market cap of $22.93 billion, a price-to-earnings ratio of 99.03, a PEG ratio of 2.68 and a beta of 1.40. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $327.65 and a 200-day simple moving average of $305.54. Insulet Corporation has a 52 week low of $227.03 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.